10.11.2015 • News

Court Says Mylan Can Uphold Perrigo Bid

A federal district court judge in New York has ruled that Mylan can continue its hostile takeover bid for Perrigo. In the case heard by the court, Perrigo claimed Mylan had made false statements by saying it expects the merged companies to see at least $800 million in pretax revenues by the end of the fourth year. However, Judge Naomi Reice Buchwald ruled that Mylan had conducted a “sound process” in devising the estimate.

Mylan has offered $75 in cash and 2.3 ordinary shares for each Perrigo ordinary share. As of September, the deal was valued at $27 billion. The Netherlands-headquartered drugmaker will be able to move forward with the acquisition if the majority of Perrigo shareholders tender their shares by Nov.13. Perrigo said it does not plan to appeal the ruling.

Virtual Event

Outsourced Biomanufacturing
Strategic Outsourcing in Biopharmaceuticals

Outsourced Biomanufacturing

April 22, 2026 | Join biopharma professionals, CDMO leaders, and supply chain innovators for a virtual event exploring the future of outsourced biomanufacturing.

Interview

Navigating Uncertainty and Driving Innovation
Meeting Pharma’s Demand for Speed, Reliability, and Flexibility

Navigating Uncertainty and Driving Innovation

Axplora CCO Arul Ramadurai discusses navigating industry uncertainty, building strategic partnerships, and advancing flexible pharmaceutical manufacturing

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.